Top 5 Most Read RNS's on Vox Markets for Thursday 23rd February 2023
Episode 1205, Feb 23, 2023, 07:52 AM
Top 5 Most Read RNS's on Vox Markets for Thursday 23rd February 2023
5. Amigo Holdings #AMGO - 3rd Quarter Results
Conversations with potential investors to underwrite a £45m equity raise continue. To date non-binding, indicative interest for between £10m to £15m of equity and £10m of exchangeable notes has been received.
Revenue was £17.8M which down 76.5% from £75.7m
4. Ascent Resources #AST - Strategic Partnership, Equity Issue & TVR
Ascent Resources announces the signature of a Strategic Collaboration Agreement with Beryl International Ltd, alongside agreeing a material equity investment by Beryl and the proposed appointment of a new Beryl nominated Non-Executive Director.
In support of the collaboration, Beryl has agreed to subscribe for £1,000,000 in new equity via a direct subscription at 4p, being an 11% premium to the closing mid-market price of 3.6 pence on 22 February 2023.
3. Rolls-Royce Holdings RR. - 2022 Full Year Results
- Underlying operating profit of £652m, £238m higher than the prior year, with the increase driven by Civil Aerospace and Power Systems
- Free cash flow from continuing operations of £505m, £2.0bn higher than the prior year, led by engine flying hour recovery
- Net debt of £3.3bn, down from £5.2bn at end 2021, due to disposals and improved cash flow
2. Helium One Global #HE1 - Company Update
Helium One Global announces that the Company has entered into a co-operation agreement with Noble, pursuant to which Helium One and Noble have agreed to cooperate in sourcing and securing a suitable drilling rig, associated services and arranging logistics as required for the Company's proposed drilling campaign.
1. Avacta Group #AVCT - Avacta Therapeutics Division Science Day
Avacta Group is today holding a Science Day, focused on its Therapeutics Division, for institutional investors and analysts as stated in the announcement on the 19 December 2022.
The event will include a detailed review of the ongoing ALS-6000-101 Phase 1a clinical trial of AVA6000, Avacta's lead pre|CISION™ tumour targeted form of the chemotherapy drug Doxorubicin, in soft tissue sarcoma, as well as an update on preclinical programmes.
5. Amigo Holdings #AMGO - 3rd Quarter Results
Conversations with potential investors to underwrite a £45m equity raise continue. To date non-binding, indicative interest for between £10m to £15m of equity and £10m of exchangeable notes has been received.
Revenue was £17.8M which down 76.5% from £75.7m
4. Ascent Resources #AST - Strategic Partnership, Equity Issue & TVR
Ascent Resources announces the signature of a Strategic Collaboration Agreement with Beryl International Ltd, alongside agreeing a material equity investment by Beryl and the proposed appointment of a new Beryl nominated Non-Executive Director.
In support of the collaboration, Beryl has agreed to subscribe for £1,000,000 in new equity via a direct subscription at 4p, being an 11% premium to the closing mid-market price of 3.6 pence on 22 February 2023.
3. Rolls-Royce Holdings RR. - 2022 Full Year Results
- Underlying operating profit of £652m, £238m higher than the prior year, with the increase driven by Civil Aerospace and Power Systems
- Free cash flow from continuing operations of £505m, £2.0bn higher than the prior year, led by engine flying hour recovery
- Net debt of £3.3bn, down from £5.2bn at end 2021, due to disposals and improved cash flow
2. Helium One Global #HE1 - Company Update
Helium One Global announces that the Company has entered into a co-operation agreement with Noble, pursuant to which Helium One and Noble have agreed to cooperate in sourcing and securing a suitable drilling rig, associated services and arranging logistics as required for the Company's proposed drilling campaign.
1. Avacta Group #AVCT - Avacta Therapeutics Division Science Day
Avacta Group is today holding a Science Day, focused on its Therapeutics Division, for institutional investors and analysts as stated in the announcement on the 19 December 2022.
The event will include a detailed review of the ongoing ALS-6000-101 Phase 1a clinical trial of AVA6000, Avacta's lead pre|CISION™ tumour targeted form of the chemotherapy drug Doxorubicin, in soft tissue sarcoma, as well as an update on preclinical programmes.